A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus

Article Public, Environmental & Occupational Health

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar

Elias Tayar et al.

Summary: According to this study, influenza vaccination can significantly reduce the risk of SARS-CoV-2 infection and the severity of COVID-19.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2023)

Add to Collection

Article Multidisciplinary Sciences

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Akatsuki Saito et al.

Summary: During the COVID-19 pandemic, the B.1.617.2/Delta variant has been found to be highly fusogenic and more pathogenic in infected hamsters compared to prototypic SARS-CoV-2. The P681R mutation in the spike protein of this variant enhances viral fusogenicity and pathogenicity.

NATURE (2022)

Add to Collection

Article Critical Care Medicine

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Seth Toback et al.

Summary: This study reports the safety, immunogenicity, and efficacy profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines. The results suggest that simultaneous vaccination might be a viable immunization strategy.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Critical Care Medicine

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

Ruvim Izikson et al.

Summary: This study assessed the safety and immunogenicity of concomitant administration of high-dose quadrivalent influenza vaccine (QIV-HD) and mRNA-1273 vaccine booster in older adults. The results showed no safety concerns or immune interference in the coadministration group, supporting the recommendations for co-administration. The antibody responses to influenza and SARS-CoV-2 were similar between the coadministration and QIV-HD groups.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Materials Science, Multidisciplinary

Inhalable dry powder mRNA vaccines based on extracellular vesicles

Kristen D. Popowski et al.

Summary: Respiratory diseases are a major global burden, and the development of effective therapeutics is limited. Researchers have developed a stable inhalable form of extracellular vesicles that can effectively deliver drugs to the lungs and have shown promising results in vaccine applications.

MATTER (2022)

Add to Collection

Article Virology

High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran

Seyed A. Hashemi et al.

Summary: The study reveals a high prevalence of coinfection with other respiratory viruses in SARS-CoV-2 positive dead patients, with influenza A virus being the highest and human metapneumovirus being predominant in children.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Virology

Co-infection of influenza A virus and SARS-CoV-2: A retrospective cohort study

Yuan Cheng et al.

Summary: A study analyzed data from 213 COVID-19 patients treated at Tongji Hospital in Wuhan from January 28, 2020 to March 24, 2020, revealing that 45.5% of patients tested positive for influenza A virus (IFV-A). Patients with co-infection showed similar clinical patterns to those with SARS-CoV-2 infection only, but higher levels of inflammatory markers and cardiac injury were observed in the latter group.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Cyrielle Fougeroux et al.

Summary: The study developed two SARS-CoV-2 vaccines based on capsid-like particles, showing good neutralizing antibody efficacy; mice vaccinated with the RBD-CLP vaccine demonstrated higher levels of serum anti-spike antibodies than those with soluble RBD vaccine; the RBD-CLP vaccine in mice exhibited virus neutralization antibody titers comparable to those found in patients who had recovered from COVID-19.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

Coinfection with influenza A virus enhances SARS-CoV-2 infectivity

Lei Bai et al.

Summary: The upcoming flu season in the Northern Hemisphere coinciding with the COVID-19 pandemic poses a potential threat to public health. Research shows that influenza A virus infection significantly enhances the infectivity of SARS-CoV-2, leading to increased viral load and more severe lung damage in coinfected individuals. Preventing influenza A infection is crucial in controlling the spread of COVID-19.

CELL RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Rajeka Lazarus et al.

Summary: This study assessed the safety of concomitant administration of COVID-19 and influenza vaccines. The results showed that simultaneous vaccination with ChAdOx1 or BNT162b2 and an age-appropriate influenza vaccine raised no safety concerns and did not adversely affect immune responses.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Koen B. Pouwels et al.

Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques

Hyon-Xhi Tan et al.

Summary: The study compared the immunogenicity of spike proteins (S) and receptor binding domain (RBD) in SARS-CoV-2 vaccines in mice and macaques, finding that S was highly immunogenic in mice while RBD was comparatively poor. Both S and RBD vaccines were similarly immunogenic in macaques, inducing serological neutralising activity exceeding convalescent human levels.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Immunology

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Nikolaos C. Kyriakidis et al.

Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.

NPJ VACCINES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design

Julia Stowe et al.

Summary: The study found that influenza patients had a lower risk of SARS-CoV-2 infection, but those with coinfections had a higher risk of death, especially in terms of ventilator use and intensive care unit admission.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates

Linling He et al.

Summary: By combining antigen optimization and nanoparticle display, researchers developed vaccine candidates for SARS-CoV-2 and enhanced the neutralizing antibody response of the vaccines. In mouse experiments, purification of tag-free vaccines specific for RBD was achieved using an antibody column, and the presented SARS-CoV-2 vaccine candidates elicited higher levels of neutralizing antibodies and T cell immune responses.

SCIENCE ADVANCES (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

Add to Collection

Article Nanoscience & Nanotechnology

Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19

Zhenhua Li et al.

Summary: The authors demonstrate that nanovesicles coated with lung spheroid cell membranes expressing angiotensin-converting enzyme 2 can bind and neutralize SARS-CoV-2, potentially serving as a therapeutic agent for treating COVID-19.

NATURE NANOTECHNOLOGY (2021)

Add to Collection

Article Immunology

Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge

R. Glenn King et al.

Summary: The study found that a single intranasal dose of AdCOVID vaccine can generate a strong and focused immune response against RBD, including mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4(+) and CD8(+) T cells with a T(h)1-like cytokine expression profile. Additionally, a single AdCOVID dose can result in immunity sustained for over six months and completely protect K18-hACE2 mice from lethal SARS-CoV-2 challenge, preventing weight loss and mortality, indicating that AdCOVID promotes concomitant systemic and mucosal immunity and serves as a promising vaccine candidate.

VACCINES (2021)

Add to Collection

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study

Jillian H. Hurst et al.

Summary: This study found that Hispanic ethnicity and having an infected sibling close contact are associated with increased risk of SARS-CoV-2 infection among children, while asthma is associated with decreased risk. Children aged 6-13 years are more likely to be asymptomatic, while adolescents are more likely to have influenza-like, gastrointestinal, and sensory symptoms.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Petra Mlcochova et al.

Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil

Guenther Fink et al.

Summary: The study found that COVID-19 patients who received recent inactivated influenza vaccination in Brazil had lower odds of needing intensive care treatment, requiring invasive respiratory support, and death. These protective effects were more significant when the vaccine was administered after symptom onset and among younger patients.

BMJ EVIDENCE-BASED MEDICINE (2021)

Add to Collection

Article Hospitality, Leisure, Sport & Tourism

Hospitality and tourism industry amid COVID-19 pandemic: Perspectives on challenges and learnings from India

Vikrant Kaushal et al.

Summary: The study examines the major challenges faced by the tourism and hospitality industry amid the COVID-19 outbreak, with a focus on themes like Human Resource Management, Health and Hygiene, Continuity and Concerns. The research draws on interviews with senior professionals in the industry and education services to provide insights and recommendations for decision makers.

INTERNATIONAL JOURNAL OF HOSPITALITY MANAGEMENT (2021)

Add to Collection

Article Immunology

Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study

Robertus van Aalst et al.

VACCINE (2020)

Add to Collection

Editorial Material Medicine, General & Internal

A novel coronavirus outbreak of global health concern

Chen Wang et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Qihui Wang et al.

CELL (2020)

Add to Collection

Article Immunology

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Wanbo Tai et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Review Microbiology

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

Ning Wang et al.

FRONTIERS IN MICROBIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Abishek Chandrashekar et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao et al.

SCIENCE (2020)

Add to Collection

Article Virology

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China

Qiang Ding et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 and influenza virus co-infection

Elena Cuadrado-Payan et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sin Fun Sia et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Lianpan Dai et al.

CELL (2020)

Add to Collection

Article Immunology

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

Dorottya Laczko et al.

IMMUNITY (2020)

Add to Collection

Review Immunology

Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs

Jesus Zepeda-Cervantes et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Chemistry, Multidisciplinary

Engineering Antiviral Vaccines

Xingwu Zhou et al.

ACS NANO (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques

Malika Aid et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Lisa H. Tostanoski et al.

NATURE MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Yixuan J. Hou et al.

SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Article Infectious Diseases

Co-infection with SARS-CoV-2 and influenza A virus

Shuhei Azekawa et al.

IDCASES (2020)

Add to Collection

Article Immunology

Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15

James G. Donahue et al.

VACCINE (2019)

Add to Collection

Review Virology

Influenza vaccine: Where are we and where do we go?

Mohsen Keshavarz et al.

REVIEWS IN MEDICAL VIROLOGY (2019)

Add to Collection

Article Allergy

Live attenuated influenza vaccine use and safety in children and adults with asthma

Jonathan Duffy et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2017)

Add to Collection

Article Immunology

Brucella abortus S19 and RB51 vaccine immunogenicity test: Evaluation of three mice (BALB/c, Swiss and CD-1®) and two challenge strains (544 and 2308)

Karina Leite Miranda et al.

VACCINE (2015)

Add to Collection

Article Engineering, Biomedical

The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes

Changhui Fu et al.

BIOMATERIALS (2013)

Add to Collection

Article Biotechnology & Applied Microbiology

Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

Martin A. Maier et al.

MOLECULAR THERAPY (2013)

Add to Collection

Article Chemistry, Physical

Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes

Ashley L. St. John et al.

NATURE MATERIALS (2012)

Add to Collection

Review Immunology

IL-17 and Th17 Cells

Thomas Korn et al.

ANNUAL REVIEW OF IMMUNOLOGY (2009)

Add to Collection

Article Multidisciplinary Sciences

Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

Rebecca J. Garten et al.

SCIENCE (2009)

Add to Collection

Article Immunology

Antibody quantity versus quality after influenza vaccination

JingQi Feng et al.

VACCINE (2009)

Add to Collection

Article Immunology

Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections

Shai Ashkenazi et al.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)

Add to Collection

A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus

Related references

Export Citation

Share Paper